Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $12,030.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $4.01, for a total transaction of $12,030.00. Following the completion of the transaction, the director now owns 141,950 shares of the company’s stock, valued at approximately $569,219.50. This trade represents a 2.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

John Joseph Johnston also recently made the following trade(s):

• On Monday, October 28th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $3.72, for a total transaction of $11,160.00.

MaxCyte Trading Up 1.2 %

Shares of NASDAQ:MXCT opened at $4.16 on Thursday. The company has a 50 day moving average of $3.79 and a 200-day moving average of $4.01. The firm has a market cap of $439.67 million, a P/E ratio of -12.23 and a beta of 1.37. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The company had revenue of $8.16 million for the quarter, compared to analysts’ expectations of $7.50 million. During the same period last year, the firm earned ($0.11) EPS. Equities research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MXCT. Intech Investment Management LLC bought a new position in shares of MaxCyte during the 3rd quarter valued at about $51,000. China Universal Asset Management Co. Ltd. lifted its stake in MaxCyte by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after purchasing an additional 7,930 shares during the last quarter. Verition Fund Management LLC boosted its holdings in MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after buying an additional 6,045 shares in the last quarter. Creative Planning grew its position in MaxCyte by 33.6% in the third quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after buying an additional 7,212 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of MaxCyte by 22.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after buying an additional 5,927 shares in the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.